April 25, 2024 03:00 PM EDT
FDA+
Marketing

FDA re­vis­es guid­ance on biosim­i­lar pro­mo­tion­al la­bels and ad­ver­tis­ing

Beth Snyder Bulik

Senior Editor

Fol­low­ing a re­cent move to ask Con­gress to elim­i­nate the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars, the FDA on Wednes­day pro­posed up­dat­ed guid­ance on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times